Phase I, Open-label, Dose Escalation Study to Assess Safety and Tolerability of SOR-C13 in Subjects With Advanced Solid Tumors Commonly Known to Express the TRPV6 Ion Channel

Trial Profile

Phase I, Open-label, Dose Escalation Study to Assess Safety and Tolerability of SOR-C13 in Subjects With Advanced Solid Tumors Commonly Known to Express the TRPV6 Ion Channel

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs SOR C13 (Primary)
  • Indications Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Soricimed Biopharma
  • Most Recent Events

    • 01 Feb 2017 Results published in the Investigational New Drugs
    • 27 Sep 2016 According to a Soricimed Biopharma media release, the US FDA has granted orphan drug designation to SOR-C13 for the treatment of pancreatic cancer.
    • 06 Jul 2016 Results published in Soricimed Biopharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top